Back to mobile site

Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Stock remains constrained by questions & remaining catalyst pathway'

October 13, 2026 8:59 AM EDT Send to a Friend
Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb Co. (NYSE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login